Michelson Philanthropies’ Chief Scientific Officer Thomas Conlon joins the 2022 Milken Institute Future of Health Summit alongside a panel of vaccine development and biomedical experts to discuss the potential and advancements of mRNA.
Messenger RNA, or mRNA, has been a focus of research for scientists and drug developers for many years. It jumped to the forefront of the public consciousness when it rapidly and successfully deployed as the platform for COVID-19 vaccines. The technology, however, promises to address a wider range of conditions, from cancers to cardiovascular disease to a broad array of infectious diseases. Learn more about the inner workings of mRNA and its promise as a treatment modality.
Senior Writer, Medicine, Editorial Director of Events, STAT News
Member Researcher and Surgical Oncologist, David M. Rubenstein Center for Pancreatic Cancer Research
Chief Scientific Officer, Michelson Philanthropies and the Michelson Found Animals Foundation
President and CEO, International AIDS Vaccine Initiative (IAVI)
Managing Partner, BioImpact Capital and Managing Director, MPM Capital
Director, Vaccine Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health